A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors
Latest Information Update: 06 Aug 2025
At a glance
- Drugs SKB-410 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 11 Apr 2025 Status changed from not yet recruiting to recruiting.
- 18 Feb 2025 New trial record